Prothena (STU:0PT) Short Interest


STU:0PT Prothena Corp PLC STU:0PT
74 GF Score
Price €8.72
GF Value €12.85
! 3 Warning Signs
View Full Analysis

What is Prothena Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:0PT vs EDIT, ACHV, XOMA: Short Interest Comparison

For the Biotechnology subindustry, Prothena's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prothena Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prothena's Short Interest distribution charts can be found below:

* The bar in red indicates where Prothena's Short Interest falls into.


STU:0PT
74GF Score
Prothena Corp PLC STU:0PT
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Prothena (STU:0PT) Overvalued in 2026?

Based on GuruFocus' analysis, Prothena stock appears to be undervalued. The current stock price of €8.72 is trading 32.2% below its estimated GF Value™ of €12.85.

Key valuation signals for STU:0PT:

  • Short Interest:
  • GF Value™: €12.85 vs. price of €8.72 (32.2% below fair value)
  • GF Score™: 74/100 with 3 warning signs

No single metric tells the full story. See the STU:0PT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prothena Business Description

Other Exchanges PRTA:USA0Y3M:UK0PT:Germany
Address 77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, Dublin, IRL, D02 VK60
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
74GF Score

Get the complete analysis for STU:0PT

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.72
Price
€12.85
GF Value